Although further studies will be needed to evaluate the antitumor efficacy of PTK7-CAR T cells in a more clinically relevant setting such as using PDXs and patient-derived cancer cell lines, our data support PTK7-CAR T cells as a viable therapeutic option for lung cancers and many other solid cancers with PTK7 overexpression given that it is impractical to develop blocking antibodies or small-molecule inhibitors as typically done with receptor tyrosine kinases due to PTK7’s lack of catalytic activity. The gene discussed is PTK7; the disease is cancer.